The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium
- PMID: 23402454
- DOI: 10.1586/erp.12.88
The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium
Abstract
Background: Proton pump inhibitors (PPIs) and statins have been among the top three most prescribed medicines in Belgium for more than a decade. Multiple demand-side measures have been introduced to improve rational prescribing generally, as well as for these two classes.
Objectives: First, assessing the influence of general and specific reforms introduced in Belgium since 1997 on utilization and expenditure of the PPIs and statins. Second, suggesting additional measures to further improve rational prescribing based on experiences in other European countries.
Methods: A retrospective observational study for assessing the influence of multiple initiatives in Belgium on utilization and expenditure of the PPIs and statins from 1997 to 2009 was carried out. Data were extracted from the administrative database Pharmanet. Utilization was measured in terms of defined daily doses (DDDs) and DDDs/thousand inhabitants per day.
Results: Multiple reforms, including co-payments and reference pricing, appreciably enhanced rational prescribing for both PPIs and statins following generic availability. There was an eightfold increase in PPI utilization between 1997 and 2009, but only a twofold increase in reimbursed expenditure, helped by decreasing expenditure/DDD for the PPIs from €1.91 in 1997 to €0.52 in 2009. Similarly, a 20-fold increase was observed in statin utilization between 1997 and 2009, but only a fivefold increase in reimbursed expenditure, helped again by reimbursed expenditure/DDD decreasing from €2.05 in 1997 to €0.57 in 2009. Reduced co-payments for larger packs enhanced their prescription.
Conclusion: Multiple reforms influenced utilization patterns and expenditure for the PPIs and statins, as well as the pack sizes dispensed. Additional demand-side measures are needed to further enhance rational prescribing, which can build on the experiences in other countries. These can be potentially transferred to other classes.
Similar articles
-
Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):125-30. doi: 10.1586/erp.11.98. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 22280202
-
Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):115-24. doi: 10.1586/erp.11.90. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 22280201
-
Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):475-84. doi: 10.1586/erp.09.43. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19817531
-
The impact of reference-pricing systems in Europe: a literature review and case studies.Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):729-37. doi: 10.1586/erp.11.70. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 22098289 Review.
-
Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.Expert Rev Pharmacoecon Outcomes Res. 2009 Dec;9(6):569-81. doi: 10.1586/erp.09.58. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19941434 Review.
Cited by
-
Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016.Therap Adv Gastroenterol. 2020 Mar 19;13:1756284820913743. doi: 10.1177/1756284820913743. eCollection 2020. Therap Adv Gastroenterol. 2020. PMID: 32218806 Free PMC article.
-
Time trends in statin utilisation and coronary mortality in Western European countries.BMJ Open. 2016 Mar 30;6(3):e010500. doi: 10.1136/bmjopen-2015-010500. BMJ Open. 2016. PMID: 27029774 Free PMC article.
-
Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia.BMJ Qual Saf. 2020 May;29(5):365-373. doi: 10.1136/bmjqs-2019-009897. Epub 2019 Oct 22. BMJ Qual Saf. 2020. PMID: 31641029 Free PMC article.
-
Key Considerations From a Health Authority Perspective When Proton Pump Inhibitors Are Used to Treat Gastroesophageal Reflux Disease (GERD) and Their Implications.Cureus. 2022 Nov 26;14(11):e31918. doi: 10.7759/cureus.31918. eCollection 2022 Nov. Cureus. 2022. PMID: 36447806 Free PMC article. Review.
-
Awareness, attitude and behavior regarding proton pump inhibitor among medical staff in the Southwest of China.BMC Health Serv Res. 2019 Nov 21;19(1):880. doi: 10.1186/s12913-019-4725-6. BMC Health Serv Res. 2019. PMID: 31752835 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials